Surface-enhanced Raman spectroscopy for tellurium detection by AgNPs-loaded 3D porous graphene hydrogel

Micro & nano letters

article

Xiaojiao Zhou¹  Jianwei Gao¹  Hua Huang¹  Qingsheng Wu¹  Xiang Ji¹ 

[1] Key Laboratory of Neutronics and Radiation Safety, Institute of Nuclear Energy Safety Technology, Chinese Academy of Science;University of Science and Technology of China

关键词: tellurium;    surface enhanced Raman scattering;    silver;    nanoparticles;    graphene;    hydrogels;    porous materials;    porosity;    pH;    self-assembly;    chemical sensors;    nanofabrication;    nanosensors;    tellurium detection;    facile ethylenediamine-induced self-assembly method;    silver nanoparticle-loaded 3D porous graphene hydrogel;    robust graphene-based monoliths;    porous structure;    pH;    concentration dependent surface-enhanced Raman spectroscopy;    Ag-C;    Te;   

DOI  :  10.1049/mnl.2017.0297

学科分类：计算机科学（综合）

来源: Wiley

【 摘 要 】

Background: Successful therapy of chronic myeloid leukaemia (CML) relies on close monitoring of patients’ response to therapy using the standardised real-time quantitative polymerase chain reaction (RQ-PCR) or fluorescent in situ hybridisation (FISH) at 3, 6 and 12 months. The European LeukemiaNet has published recommended therapeutic targets for frontline therapy at specific time points. Imatinib, a tyrosine kinase inhibitor, is used for the frontline treatment of chronic and accelerated phase CML in our setting. Aim: The aim of this study was to evaluate treatment response of patients with CML in chronic or accelerated phase treated with imatinib during the first 2 years of therapy. Setting: Universitas Academic Hospital, South Africa. Methods: In this analytical cohort study, a retrospective file review of all chronic and accelerated phase CML diagnosed between 2009 and 2016, who were initiated on imatinib as front-line therapy, was performed. Clinical and laboratory data were collected for different time intervals as recommended by European LeukemiaNet guidelines. Results: Thirty-seven patients met the inclusion criteria. An optimal response was obtained in 82.6%, 54.2%, 50.0% and 66.7% of patients at 3, 6, 12 and 18 months, respectively. Conclusion: The patient outcomes were comparable with other published studies, with two-thirds of patients achieving an optimal response at 18 months. It is important, however, that factors contributing to suboptimal responses in the remaining third of patients should be explored.

【 授权许可】

CC BY|CC BY-ND|CC BY-NC|CC BY-NC-ND